AstraZeneca plc vs Indonesia Energy Corporation Limited — how do they compare? AstraZeneca plc trades at $168.51 (market cap $253.13B), while Indonesia Energy Corporation Limited trades at $2.9 (market cap $45.24M). The key difference: AstraZeneca plc is far larger — about 5595.3× Indonesia Energy Corporation Limited's market cap, and AstraZeneca plc pays a 1.92% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| AZN | INDO | |
|---|---|---|
Market Cap | $253.13B | $45.24M |
Sector | Health | Energy |
52-Week High | $209.48 | $6.74 |
52-Week Low | $137.44 | $2.49 |
Enterprise Value | $279.37B | $40.61M |
Dividend Yield | 1.92% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
INDO trades at $3.00, up 9.49% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to drive revenue growth and reduce losses. Key risks include sustained negative profitability and operational challenges in oil exploration. Upside potential exists if production targets are met, but investors face significant financial and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →